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Abstract
Background: Kaposi’s sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) are related human tumor
viruses that cause primary effusion lymphomas (PEL) and Burkitt’s lymphomas (BL), respectively. Viral genes
expressed in naturally-infected cancer cells contribute to disease pathogenesis; knowing which viral genes are
expressed is critical in understanding how these viruses cause cancer. To evaluate the expression of viral genes, we
used high-resolution separation and mass spectrometry coupled with custom tiling arrays to align the viral
proteomes and transcriptomes of three PEL and two BL cell lines under latent and lytic culture conditions.
Results: The majority of viral genes were efficiently detected at the transcript and/or protein level on manipulating
the viral life cycle. Overall the correlation of expressed viral proteins and transcripts was highly complementary in
both validating and providing orthogonal data with latent/lytic viral gene expression. Our approach also identified
novel viral genes in both KSHV and EBV, and extends viral genome annotation. Several previously uncharacterized
genes were validated at both transcript and protein levels.
Conclusions: This systems biology approach coupling proteome and transcriptome measurements provides a
comprehensive view of viral gene expression that could not have been attained using each methodology
independently. Detection of viral proteins in combination with viral transcripts is a potentially powerful method for
establishing virus-disease relationships.
Background
Kaposi’s sarcoma-associated herpesvirus (KSHV) and
Epstein-Barr virus (EBV) are related gamma-herpesviruses
that cause a variety of human B cell and non-B cell malig-
nancies. EBV was identified in 1964 as the etiological
agent of Burkitt’s lymphoma (BL) [1], and is detected in
the majority of African endemic BL [2-4]. KSHV was iden-
tified in 1994 as the etiological agent of Kaposi’s sarcoma
[5], and later detected in all cases of primary effusion lym-
phoma (PEL) [6,7]. In a unique example of co-infection,
60-90% of PEL cases carry EBV in addition to KSHV
(reviewed in [8]). Both KSHV and EBV encode genes that
promote proliferation, enhance survival, and inhibit host
immune responses (reviewed in [9-11]). Unfortunately, the
expression of these genes also contributes to viral malig-
nancies if the host’s immune system is compromised.
Preliminary annotation of viral genes is typically based
on sequence homology to related viruses and in silico
prediction of open reading frames (ORFs) typically
defined by a minimum of 100 amino acids with a preced-
ing start methionine [12,13]. New viral genes can also be
proposed using computer-based search algorithms
revealing homology to known cellular and viral genes.
Subsequent confirmation of preliminary annotation relies
on transcript analysis, such as rapid amplification of
cDNA ends (RACE), northern probing, or direct sequen-
cing. Several genes encoded by KSHV and EBV as well as
other viruses do not conform to traditional strategies of
annotation, requiring integration of multiple methods
and frequently, extensive experimentation, for their
detection. Examples include Epstein-Barr virus Encoded
RNAs (EBERs) and Poly-Adenylated Nuclear RNA (PAN)
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and C which use non-canonical start codons [16,17];
antisense-ORF50 which encodes only short peptides [18];
and genes with limited sequence homology to known
genes, including Epstein-Barr Nuclear Antigen 1
(EBNA1) [19,20] and Latency Associated Nuclear Anti-
gen 1 (LANA1) [21].
In this study, we applied a systems biology approach to
identify novel viral genes and to assess patterns of viral
gene expression for EBV and KSHV. We designed custom
tiling arrays to interrogate viral transcriptomes and per-
formed high-resolution, liquid chromatography (LC) with
tandem-mass spectrometry (MS/MS) to interrogate viral
proteomes. By integrating both transcriptome and pro-
teome data, we gained a more comprehensive assessment
of viral gene expression. Our strategy using human B cell
lymphoma cell lines singly-infected, dually-infected, or not
infected either by KSHV and/or EBV provided a particu-
larly well-controlled system for this assessment. We
manipulated the pattern of viral gene expression by
experimentally inducing virus lytic reactivation from
latency. Paired lytic and latent samples provided a com-
parison of the full range of viral gene expression that is
theoretically detectable in a particular virus with the
restricted expression of viral genes required for tumori-
genesis. Detection of latent genes can be obscured by a
fraction of spontaneously-lytic cells in a population; thus,
tightly-latent cell lines and spontaneously-lytic cell lines
were compared in this study. In general, quantitative pro-
teomic detection of viral peptides closely followed viral
gene hybridization data.
We detected known, annotated viral genes from KSHV
(NC_009333, U75698.1, and HQ404500.1) and EBV
(NC_007605, and NC_009334), as well as multiple viral
genes that have been previously described but remain
unannotated relative to their curated viral genomes. Addi-
tionally, we identified several novel transcripts and pro-
teins in both KSHV and EBV, including the first detection
of a novel protein corresponding to the unannotated tran-
script antisense to vIL6 and ORF2 of KSHV. The align-
ment of the transcriptome and proteome data from PEL
and BL cell lines produces a more precise classification of
latent genes for both viruses, allows quantification of
spontaneous-lytic induction, and more importantly, facili-
tates virus gene discovery.
Results
Assessing Viral Transcriptomes and Proteomes
Tiling array experiments were performed to assess viral
transcriptomes using five, untreated B cell lines, includ-
ing three PELs and two BLs (Table 1). The PEL cell line
BC-1 was additionally assessed using lytic culture condi-
tions by treating with sodium butyrate (NaB) and 12-O-
tetradecanoylphorbol-13-acetate (TPA) for 48 hours.
BJAB, an EBV-negative/KSHV-negative BL cell line, was
used as the reference sample for all arrays. As a control
experiment, BJAB was tested in both Cy3 and Cy5 chan-
nels; KSHV and EBV transcripts were not discernible
above background fluorescence (data not shown). Tran-
script expression was evaluated using a cutoff of ≥1.25-
fold normalized signal to eliminate false positives and
minimize false negatives (see Methods). Using this cut-
off, no KSHV transcripts were detected over the refer-
ence sample in the KSHV-negative cell line MutuIII
(Table 1 and additional file 1, Table S1), and no EBV
transcripts were detected over the reference sample in
the EBV-negative cell line BCBL-1 (Table 1 and addi-
tional file 1, Table S2). Select cellular genes probed as
controls, e.g., GAPDH, were detected in all samples
above background fluorescence (additional file 1, Table
S3). The expression patterns of either KSHV or EBV
transcriptomes were compared pairwise for each sample
using Pearson’s correlation coefficients; technical repli-
cates of either latent or lytic BC-1 samples were very
strongly correlated (additional file 1, Table S4).
We also detected a set of transcripts corresponding to
unannotated regions of KSHV (NC_009333) and EBV
(NC_007605) in multiple cell lines and conditions (Table 1).
In MutuIII, an EBV-positive/KSHV-negative BL cell line,
transcripts from 28 annotated genes and 1 novel EBV gene
were detected over the reference sample. In BCBL-1, a
KSHV-positive/EBV-negative PEL cell line, transcripts from
79 annotated genes and 8 unannotated/novel KSHV genes
were detected over the reference sample. In JSC-1, a KSHV-
positive/EBV-positive PEL cell line, transcripts from 67
annotated and 6 unannotated/novel KSHV genes were
detected over the reference sample; transcripts from 41
annotated and 2 novel EBV genes were detected. In BC-1,
another KSHV-positive/EBV-positive PEL cell line, tran-
scripts from 34 annotated and 4 unannotated/novel KSHV
genes were detected over the reference sample; transcripts
from 22 annotated and 1 novel EBV genes were detected.
Additional annotated and unannotated viral transcripts
were detected over the reference sample on lytic induction







KSHV EBV KSHV EBV KSHV EBV
MutuIII -+ 02 8 0 1
BCBL-1 +- 79 0 8 0
JSC-1 ++ 67 41 6 2
BC-1 (latent) ++ 34 22 4 1
BC-1 (lytic) ++ 74 30 8 1
Detected transcripts: ≥1.25-fold over the reference sample
+ = virus-positive; - = virus-negative
Total possible KSHV transcripts = 88 known/annotated, 9 unannotated/novel
Total possible EBV transcripts = 89 known/annotated, 2 novel
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genes and 30 annotated and 1 novel EBV genes detected.
Whole cell lysates were used with LC-MS/MS analysis
to assess the proteomes from two PEL cell lines, cultured
under latent and lytic conditions (Table 2). Peptides that
were not assigned to known cellular proteins were mapped
to ORFs at least 10 amino acids long in the 6-frames of
KSHV (U75698.1; HQ404500.1) or EBV (NC_007605;
NC_009334). Collectively, 2,469 peptide spectra (or
counts) were detected across all samples corresponding to
68 of the 85 annotated KSHV proteins (Table 2 and addi-
tional file 1, Table S5). A total of 238 peptide spectra were
detected corresponding to 42 of the 83 annotated EBV
proteins (Table 2 and additional file 1, Table S6), and one
additional peptide spectrum was detected corresponding
to the previously-described, unannotated protein in an
alternative reading frame (ARF) of EBV’s EBNA1 [22]. An
additional set of peptides was also identified corresponding
to unannotated ORFs in KSHV or EBV (additional file 1,
Table S5 and Table S6). These peptides represent puta-
tive viral proteins, but were only considered novel proteins
if they fulfilled two criteria: 1) at least one peptide was
detected in multiple samples, and 2) in one of these sam-
ples, two or more peptide spectra were detected. The lack
of an identifiable start methionine was not an exclusionary
criterion. Observed spectra from unique peptide sequences
were totaled together if they mapped to the same ORF.
Altogether, 21 peptide spectra were identified correspond-
ing to 3 novel KSHV proteins, and 20 peptide spectra
were identified corresponding to 3 novel EBV proteins. A
large number of putative peptides did not meet both cri-
teria (148 peptides in KSHV and 91 peptides in EBV; addi-
tional file 1, Table S7).
KSHV peptide spectra were detected in latent BCBL-1 as
0.731% of all observed spectra (754/103,113) and in lytic
BCBL-1 as 1.505% of all observed spectra (1,135/75,435)
(Table 2). KSHV peptide spectra were detected in latent
BC-1 as 0.077% of all observed spectra (64/82,992) and in
lytic BC-1 as 0.629% of all observed spectra (537/85,409)
consistent with KSHV having tight latency in BC-1 cells
compared to BCBL-1 in standard culture [23]. EBV pep-
tide spectra were detected in latent BC-1 as 0.035% of all
observed spectra (29/82,992) and in lytic BC-1 as 0.269%
of all observed spectra (230/85,409). Detection of fewer
EBV peptides than KSHV peptides is consistent with more
abundant expression of KSHV genes than EBV genes in
dually-infected PEL, although this also may be due in part
to differences in KSHV and EBV copy number [24]. The
number of viral peptide spectra increase upon lytic induc-
tion as expected; this increase is less pronounced for
BCBL-1 (~1.5-fold for KSHV) than for BC-1 (~8-fold for
either KSHV or EBV).
Aligning Viral Proteomes and Transcriptomes
Alignments were made between viral proteomes and viral
transcriptomes to determine their degree of overlap (Table
3 and additional file 1, Table S8); alignments include any
known, unannotated, or novel viral genes with a distinct
match between one transcript and one protein. Analysis of
matched proteins-to-transcripts, relative to the total
observed KSHV proteins per sample, shows alignment of
50% for latent BC-1, 88% for lytic BC-1, and 95% for latent
BCBL-1. A similar analysis for EBV has an alignment of
14% for latent BC-1 and 32% for lytic BC-1. Combining the
list of EBV proteins detected in BC-1 reveals that 68% of
these proteins are mature virion proteins (MVPs) (e.g., cap-
sid, tegument, envelope, etc. [25]). In latent BC-1, 7 of the
10 proteins from KSHV without matched transcripts are
also detected upon lytic induction; 8 of these proteins have
detectable transcripts in lytic BC-1. By contrast, BC-1 lytic
and BCBL-1 latent samples have very few detected proteins
from KSHV without matched transcripts.
We do not detect any proteins for non-coding viral tran-
scripts, such as EBERs, PAN, and primary microRNAs
(miRNAs), while peptides were readily detected for coding
mRNAs. These non-coding transcripts were removed for
adjusted transcript-to-protein alignments (Table 3 and
additional file 1, Table S8). Analysis of matched tran-
scripts-to-proteins, relative to the total observed KSHV
transcripts per sample, shows an alignment of 31% for
latent BC-1, 51% for lytic BC-1, and 68% for latent BCBL-
1. A similar analysis for EBV has an alignment of 11% for
latent BC-1 and 46% for lytic BC-1. Tiling arrays are com-
prehensive and can detect the full range of viral transcripts
from KSHV and EBV, whereas LC-MS/MS is more limited
in its dynamic range; thus, the number of viral proteins
that may be expressed is likely under-represented (see
Table 2 Total Peptide Spectra with Viral Assignment
Peptide
Spectra:
Total Viral Annot. Unannot.
BCBL-1
Latent 103113 KSHV 754 0.731% = 751 (55) 3 (2)






Latent 82992 KSHV 64 0.077% = 57 (19) 7 (3)
EBV 29 0.035% = 21 (12) 8 (4)
Lytic 85409 KSHV 537 0.629% = 530 (41) 7 (2)
EBV 230 0.269% = 217 (39) 13 (3)
Total spectra for all observed peptides are reported in bold.
The percentage of viral peptide spectra from the total number of observed
spectra is indicated in italics.
The total number of viral proteins detected is indicated in parentheses.
Total possible KSHV proteins = 85 known; 3 novel
Total possible EBV proteins = 83 known; 4 unannotated/novel
Annot. = Annotated; Unannot. = Unannotated
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and proteomes improve for both KSHV and EBV when
the lytic cycle is induced.
The total number of detected KSHV transcripts in latent
BC-1 increases 2.2-fold upon lytic induction (from 38 to
82 transcripts, respectively). The total number of detected
KSHV proteins in latent BC-1 increases 2.0-fold upon lytic
induction (from 22 to 43 proteins, respectively). The total
number of detected EBV transcripts in latent BC-1
increases 1.3-fold upon lytic induction (from 23 to 31
transcripts, respectively). The total number of detected
EBV proteins in latent BC-1 increases 2.6-fold upon lytic
induction (from 16 to 42 proteins, respectively). The total
number of detected KSHV proteins in latent BCBL-1 is
generally the same as in lytic BCBL-1 (57 and 59 proteins,
respectively), but the majority of KSHV proteins detected
in lytic BCBL-1 (85%) were already detected in BCBL-1
without lytic induction.
In addition to tabulated alignments, graphic alignments
were generated and grouped in three tiers: 1) viral gene
annotation, 2) viral transcriptomes, and 3) viral pro-
teomes (legends of Figure 1 and Figure 2). Complete
alignments for both KSHV (additional file 2, Figure S1)
and EBV (additional file 3, Figure S2) were generated for
each cell line. Specific regions of KSHV (Figure 1) and
EBV (Figure 2) were chosen to depict selected cell lines
and conditions in greater detail with respect to novel
viral genes and latent gene classification.
Novel KSHV Annotation
Analysis of viral transcriptomes identified several unan-
notated transcripts antisense to known genes (Table 4).
Specific transcripts detected in KSHV without any prior
characterization include antisense-K4s (K3.5; Figure 1A),
antisense-PAN/K7 (K7.3; Figure 1A), and antisense-
ORF58/59 (K11.5; Figure 1D). Additional unannotated
transcripts have been previously published and are con-
sistently detected in this study (Table 4), including T6.1
and T1.5 (K4.5 and K4.7; Figure 1A), described by Tay-
lor et al, 2005 [26]; antisense-ORF50 (K7.7; Figure 1C),
described by Xu and Ganem, 2010 [18]; a transcript
antisense to the leftward-end (K1.3 or ALE; Figure 1A),
a transcript antisense to viral interleukin-6 and ORF2
(K1.5 or antisense-vIL6/ORF2; Figure 1A), and antisense
to latent transcripts, (K12.5 or ALT; Figure 1E),
described by Chandriani and Ganem, 2010 [27], and
Chandriani et al, 2010 [28]. Multiple short, putative
peptides are associated with several of these unanno-
tated transcripts (additional file 1, Table S5).
The antisense-vIL6/ORF2 transcript is associated with
a novel protein (Figure 1F and Table 4). This novel pro-
tein is the fourth most frequently-detected in latent BC-
1 based on total peptide spectra corresponding to one
ORF (3 total). The antisense-vIL6/ORF2 peptide is also
detected in lytic BC-1, and in both latent and lytic
BCBL-1 samples (asterisk in Figure 1A); the number of
peptide spectra increase upon lytic induction in both
BC-1 and BCBL-1. Antisense-vIL6/ORF2 contains a
short, predicted ORF (either 43 or 54 amino acids in
length) with two possible start methionines (Figure 1F).
There is also an ARF of ORF75 that is calculated to be
85 amino acids in length (K14.5; Figure 1E and Table
4), as well as an ARF of ORF30 that is calculated to be
16 amino acids in length (K7.5; Figure 1B and Table 4).
Both ARF proteins met our criteria as novel proteins,
although their transcripts cannot be detected distinct
from their known-frame counterparts, and thus, were
not evaluated for proteome/transcriptome alignment.
The ARF-ORF75 peptide is detected in both latent and
lytic BC-1 samples, and the ARF-ORF30 peptide is
detected in latent BC-1 and latent BCBL-1.
A3 ’-bias of fluorescently-labeled transcripts (see
Methods) reveals previously unrecognized mRNA
extensions of known viral genes at their 3’-ends, includ-
ing ORF4, ORF6, K5 (Figure 1A), and ORF69 (Figure
1E). We also found evidence that two ORFs, K12 and
K1, begin upstream of their currently annotated start
sites. For K12, multiple unique peptide sequences are
detected within upstream repeats and may correspond
Table 3 Proteome and Transcriptome Alignments
Summary
Detected Viral Genes (Tallies) Aligned%
Transcripts + + -- T%
§
Proteins - ++- P%
KSHV
BCBL-1 Latent 34 53 37 68% 95%
*Lytic 31 56 37 * 95%
BC-1 Latent 28 10 10 49 31% 50%
Lytic 45 37 51 0 51% 88%
EBV
BC-1 Latent 21 2 12 58 11% 14%
Lytic 18 13 28 34 46% 32%
+/- Column: # viral genes detected at only the transcript level
+/+ Column: # viral genes detected at both transcript and protein levels
(indicated in bold)
-/+ Column: # viral genes detected at only the protein level
-/- Column: # viral genes not detected at either level
Total Transcripts Possible: KSHV = 97; EBV = 93 (row totals)
Detected Transcripts (+) ≥1.25-fold over reference sample
Undetected Transcripts (-) <1.25-fold over reference sample
Total Proteins Possible: KSHV = 86; EBV = 86
Detected Proteins (+): spectra are observed with the protein
Undetected Proteins (-): spectra are not observed with the protein
Aligned% = 100% × +/+ column ÷ total detected transcripts (T%) or total
detected proteins (P%)
§Transcript-to-protein alignments (%) were adjusted to remove non-coding
RNAs from the denominator.
*BCBL-1 latent transcripts were aligned to lytic proteins (no transcript analysis
was performed with lytic BCBL-1).
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detected K12 peptide sequences are in the same frame
(Figure 1E). For K1, an upstream peptide is detected
which includes the presently assigned start methionine
(additional file 1, Table S5); this suggests that the K1
protein is larger than previously described.
Novel EBV Annotation
New transcripts detected in EBV include antisense-
EBNA3B and antisense-EBNA3C (BELF3B and BELF3C;
Figure 2D and Table 4). One novel protein in EBV is anti-
sense to BPLF1 and adjacent to the U exon of the EBNA
transcripts (BURF1; Figure 2C and Table 4). Two peptide
sequences were detected corresponding to antisense-
BPLF1, with only one spectrum detected in latent BC-1
and a total of nine spectra detected in the lytically-induced
BC-1 sample (asterisk in Figure 2C), suggesting that anti-
sense-BPLF1 is a lytic protein. This ORF has two potential
start methionines, encoding either a 220 or 236 amino
acid protein (Figure 2F). No transcript was detected over
the reference sample corresponding to this novel protein
(additional file 1, Table S2). We detected multiple peptide
sequences and spectra in an ARF of BALF3 (BALF3.5; Fig-
ure 2E and Table 4). ARF-BALF3 is calculated to be 169
amino acids in length. This novel protein maps to a repeti-
tive region insufficiently tiled by the array; thus, we cannot
characterize its associated transcripts. Finally, an ORF
upstream to BALF1 (BALF0; Figure 2E and Table 4) is
observed multiple times and is calculated to be 25 amino
acids in length. One peptide spectrum was detected corre-
sponding to the unannotated protein ARF-EBNA1, or
BKRF1.5 (Figure 2D and Table 4[22]). The ARF-EBNA1
transcript cannot be distinctly-detected from that of
EBNA1.
Latent and Lytic Evaluation of KSHV
Comparisons of transcriptomes from latent BC-1 (addi-
tional file 2, Figure S1B) with either BCBL-1 or JSC-1
(additional file 2, Figure S1D and Figure S1E)c o n f i r m s
that latent gene expression is more restricted in BC-1. The
number of KSHV transcripts detected over reference in
latent BC-1 (38 total transcripts; Table 1) is also reduced
compared to JSC-1 and BCBL-1 (73 and 87 total tran-
scripts, respectively; Table 1). Additionally, the number of
Figure 1 Selected Regions of Aligned Transcripts, Proteins, and Gene Annotations from KSHV. KSHV genes are displayed in three parts
according to strand as indicated in the Legend. 1) Annotations of viral transcripts or ORFs: purple = KSHV class I (constitutive) or KSHV class II
(latent and lytic); red = KSHV class III (lytic-only); and yellow = unannotated/novel transcript/ORF. Transcriptional splicing is joined by dashed
lines. Tick marks correspond to one kilobase-pair. 2) Viral transcriptome data: purple = BC-1 latent; orange = BC-1 lytic; and blue = BCBL-1.
Normalized transcriptional data (Log10 scale) is based on the ratio of Cy3 and Cy5 fluorescent signals (experimental and reference samples,
respectively). Tick marks correspond to tens of kilobase-pairs. 3) Viral proteome data: purple = BC-1 latent, orange = BC-1 lytic, blue = BCBL-1
latent, and dark blue = BCBL-1 lytic. The width of each raised line corresponds to ORF length. The height of each raised line (Log2 scale) is the
sum total of all peptide spectra (or counts) per ORF. Panels A-E are arranged by increasing nucleotide position of KSHV (NC_009333), spanning
from: A) 0-30.1 kbp; B) 49.9-51.2 kbp; C) 71.4-74.6 kbp; D) 83.9-96.7 kbp; and E) 116.7-134.7 kbp. *One unique peptide is detected corresponding
to the short ORF antisense-vIL6/ORF2, or K1.5 (panel A). F) The protein sequence of the full ORF from antisense-vIL6/ORF2 (K1.5) is displayed
from one stop codon to the next (hyphens). Putative start methionines are in bold, italicized, and underlined. The peptide detected by LC-MS/
MS analysis is highlighted in yellow. ORF = open reading frame; FW = forward direction; RC = reverse complement direction; Kbp = kilobase-
pairs; Alt. = alternatively; a¢ = antisense; (ARF) = alternative reading frame.
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to the total KSHV peptide spectra in latent BCBL-1 (64
and 754 spectra, respectively; Table 2). The pattern of
restricted latency observed with the BC-1 cell line broadly
supports the gene expression classification described by
Sarid et al, 1998 [23]. KSHV class I genes are constitu-
tively expressed (i.e., latent), KSHV class II genes are
expressed at low constitutive levels but are induced during
lytic virus replication (i.e., latent and lytic), and KSHV
class III genes are only expressed during induction (i.e.,
lytic-only). Several distinctions between latent/lytic class II
genes and lytic-only class III genes were resolved in our
studies (Figure 1).
Using the 1.25-fold cutoff, 38 KSHV transcripts were
detected over reference with latent BC-1 conditions (Table
1) suggesting their assignment to either KSHV class I or
class II. We only analyzed the 48 hour time point after
lytic induction, which is insufficient to accurately address
which genes belong to KSHV class I or class II. What is
clear is that using a 1.25-fold cutoff these 38 genes are
readily detected over reference in latent BC-1. Several of
these genes are also detected at the protein level. Examples
of KSHV genes observed with multiple peptide spectra in
latent BC-1 include vIL6 (27 total; Figure 1A); viral inter-
feron regulatory factor 1, or vIRF1 (2 total; Figure 1D);
vIRF3, also known as LANA2 (4 total; Figure 1D); and
LANA1 (2 total; Figure 1E), consistent with each of these
genes being expressed during latency.
In addition to latent genes, select lytic and virion-asso-
ciated proteins are sensitively detected across all samples.
One peptide spectrum corresponding to ORF25, KSHV’s
major capsid protein (MCP), was detected in latent BC-1
and 12 peptide spectra were detected upon lytic induc-
tion. In latent and lytic BCBL-1, 35 and 70 peptide spec-
tra were detected, respectively. The viral processivity
factor-8 (PF-8), ORF59, is detected with 7 peptide spectra
in latent BC-1 and with 214 peptide spectra upon lytic
induction. PF-8 is detected with even greater spectral
Figure 2 Selected Regions of Aligned Transcripts, Proteins, and Gene Annotations from EBV. EBV genes are displayed in three parts
according to strand as indicated in the Legend. 1) Annotations of viral transcripts or ORFs: light blue = type I EBV-latency; purple = type II EBV-
latency; dark blue = type III EBV-latency; red = lytic-only; and yellow = unannotated/novel transcript/ORF. Transcriptional splicing is joined by
dashed lines and split with star marks. Tick marks correspond to one kilobase-pair. 2) Viral transcriptome data: green = MutuIII; purple = BC-1
latent; orange = BC-1 lytic; and red = JSC-1. Normalized transcriptional data (Log10 scale) is based on the ratio of Cy3 and Cy5 fluorescent signals
(experimental and reference samples, respectively). Tick marks correspond to tens of kilobase-pairs. 3) Viral proteome data: purple = BC-1 latent,
and orange = BC-1 lytic. The width of each raised line corresponds to ORF length. The height of each raised line (Log2 scale) is indicated as the
sum total of all peptide spectra (or counts) per ORF. Panels A-E are arranged by increasing nucleotide position of EBV (NC_007605), spanning
from: A) 0-10.5 kbp; B) 32.7-44.8 kbp; C) 52.7-56.3 kbp; D) 79.3-97.7 kbp; and E) 152.6-170.1 kbp. *Two unique peptides are detected
corresponding to the ORF antisense-BPLF1, or BURF1 (panel C). F) The protein sequence of the full ORF from antisense-BPLF1 (BURF1) is
displayed from one stop codon to the next (hyphens). Putative start methionines are in bold, italicized, and underlined. The peptide sequences
detected by LC-MS/MS analysis are highlighted in yellow and blue, and their overlap is highlighted in green. ORF = open reading frame; FW =
forward direction; RC = reverse complement direction; oriP = latent origin of replication; Kbp = kilobase-pairs; Alt. = alternatively; a¢ = antisense;
(ARF) = alternative reading frame.
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tions (Figure 1D). These data indicate that while KSHV
lytic cycle protein production (e.g. structural capsid pro-
teins) is minimally found in BC-1 without induction,
spontaneous levels of lytic expression can be detected.
These proteins markedly increase after lytic induction
and are detected at higher levels in both non-induced
and induced BCBL-1.
Latent and Lytic Evaluation of EBV
The type I, II, and III latency programs of EBV’s viral gene
expression are determined by the promoters used for
active transcription in untreated culture conditions
(reviewed in [29]); EBV’s latency types are independent of
lytic-reactivation, and are not to be confused with the
three classes of KSHV gene expression. EBV-positive PEL
and BL lines were classified according to the detection of
EBV genes corresponding to these EBV-latency programs.
Viral genes were minimally reassessed according to EBV-
latency type due to varying levels of spontaneous reactiva-
tion of EBV in the cell lines assayed (detection of BZLF1,
described below [30,31]). We do not detect any of the
transcripts for Epstein-Barr nuclear antigens in the PEL
cell lines except for EBNA1 (Figure 2B and Figure 2D).
We detect the complex spliced transcripts–RPMS1, A73,
and BARF0 co-terminal transcripts–encoding the BART
(BamHI [restriction fragment] A Rightward Transcript)
miRNAs in JSC-1 and BC-1 (Figure 2E). We unexpectedly
detect EBERs (Figure 2A) which lack poly-adenylation;
EBERs are likely inefficiently labeled but still detected due
to their very high levels of expression in the majority of
EBV-positive cells [14,32]. The latent membrane protein
(LMP) -1 and -2 transcripts (Figure 2E and Figure 2A) are
not detected, although overlapping detection of BNLF2a/b
at the 3’-end of LMP1 reduces our ability to confidently
assess LMP1 expression status. Restricted expression of
EBNA1, BARTs, and EBERs is indicative of type I EBV-
latency in PELs, consistent with previous findings [31,33].
The BZLF1 transcript encoding the lytic switch protein
ZEBRA ([BamHI restriction fragment] Z Epstein-Barr
Replication Activator) is detected in JSC-1 and BC-1 (Fig-
ure 2D). Detection of BZLF1 is consistent with sponta-
neous lytic induction. We also sensitively detect lytic and
virion-associated proteins, such as EBV’sM C P ,B c L F 1 ,
Table 4 Summary of Novel and Unannotated Viral Genes
Direct. Proposed Gene Name Temporary Name 5’-ends
¥ /ORF Start 3’-end/Stop Codon Length Figure & Ref.
KSHV
Transcript FW K1.5 a¢-vIL6/ORF2 17150 18200 1.0 Kbp 1A/F
†‡
K3.5 a¢-K4s 22125 22964 0.8 Kbp 1A
K4.5 T6.1 23596 29741 6.1 Kbp 1A
§
K4.7 T1.5 24080 25585 1.5 Kbp 1A
§
K11.5 a¢-ORF58/59 94589 96779 2.2 Kbp 1D
K12.5 ALT 120570 130546 10.0 Kbp 1E
†
RC K1.3 ALE 16969 21 17.0 Kbp 1A
†
K7.3 a¢-K7/PAN 29875 28615 1.3 Kbp 1A
K7.7 a¢-ORF50 74627 71616 3.0 Kbp 1C
*
Protein FW K1.5 a¢-vIL6/ORF2 17402 17599 43 or 54 AA 1A/F
†‡
K7.5 ARF-ORF30 50806 50856 16 AA 1B
§
RC K14.5 ARF-ORF75 132195 132452 85 AA 1E
EBV
Transcript RC BELF3B a¢-EBNA3B 85090 82960 2.1 Kbp 2D
BELF3C a¢-EBNA3C 88511 87130 1.4 Kbp 2D
Protein FW BURF1 a¢-BPLF1 54414 55160 220 or 236 AA 2C/F
BKRF1.5 ARF-EBNA1 95708 96889 370 AA 2D
£
RC BALF3.5 ARF-BALF3 159401 159909 169 AA 2E
BALF0 (same) 164978 165055 25 AA 2E
KSHV and EBV nucleotide positions are based on the sequences NC_009333 and NC_007605, respectively.
Proposed gene names for KSHV and EBV follow viral nomenclature conventions described by Russo et al, 1996 [13], and Baer et al, 1984 [12], respectively. These
gene names are indicated in bold.
Temporary gene names are indicated through the text, including previously-published gene names.
Unannotated/novel viral genes are cross-referenced to figures 1 and 2, indicated in bold.
¥5’-ends are less well detected by tiling array, and are therefore approximate values.
§Taylor et al, 2005 [26];
£Ossevoort et al, 2009 [22];
†Chandriani and Ganem, 2010 [27];
‡Chandriani et al, 2010 [28]; *Xu and Ganem, 2010 [18].
Direct. = direction; Ref. = reference; a¢ = antisense; ARF = alternative reading frame; ORF = open reading frame; AA = length in amino acids; FW = forward
strand; RC = reverse complement strand.
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with 4 and 35 peptide spectra in latent and lytic BC-1,
respectively; BMRF1 is associated with 5 and 72 peptide
spectra in latent and lytic BC-1, respectively.
In contrast to PELs, the BL MutuIII has detectable
EBNA2, -3A, -3C, -LP (leader protein), LMP1, and
LMP2A, and similarly has detectable EBNA1, the complex
spliced BARTs, and variably-detected EBERs (Figure 2A,
Figure 2B, Figure 2D, and Figure 2E). This pattern of gene
expression is indicative of type III EBV-latency, consistent
with previous findings for MutuIII [30]. We also variably
detect BHRF1 and BARF1 in MutuIII and PEL samples
(Figure 2B and Figure 2E). BZLF1 is not detected in
MutuIII.
Discussion
Proteome and Transcriptome Correlation for EBV
and KSHV
High-resolution separations with mass spectrometry and
custom tiling arrays were used to provide a comprehensive
measure of the expression of viral genes in a total of three
PEL and two BL cell lines. We evaluated viral proteomes
and viral transcriptomes in cells singly-infected with either
KSHV or EBV, dually-infected with both KSHV and EBV,
or containing neither virus. Latent and lytic conditions
were also used to differentially detect viral genes in
response to manipulating the viral life cycle. Altogether,
integrated proteome and transcriptome analysis was vali-
dated as a method to comprehensively detect both known
and novel viral genes expressed in naturally-infected
human cells.
Integrating viral transcriptomes with viral proteomes
resulted in efficient correlation of viral genes detected with
both methods, and compensated for the limits of detection
f o re i t h e rm e t h o da l o n e .L C-MS/MS based proteomics
proved to be more sensitive than tiling arrays in detecting
expression from lytic genes, including those reported in
mature virions [25]. An advantage of mass spectrometry
over other methods of protein detection is that a pre-exist-
ing pool of available antibodies is not required. For these
reasons, many more EBV proteins were detected in BC-1
than have been detected previously, further validating the
~2% spontaneous lytic induction of EBV in this cell line
[31,34].
This method can identify large or small proteins with or
without a start methionine, similar to the recently updated
annotation of Yersinia pestis [35]. LC-MS/MS analysis effi-
ciently detected viral peptides amongst the full cell reper-
toire. As much as 1.5% of all peptide spectra were
determined to be viral in lytic BCBL-1, and 0.73% of all
observed spectra were determined to be viral in uninduced
BCBL-1. This fraction of viral peptides is roughly compar-
able to our previous determination that 0.24% of all
detected transcripts are KSHV-derived in uninduced
BCBL-1 [36].
Tiling arrays proved more comprehensive than LC-MS/
MS, quantifying the expression of all viral genes for each
sample. Tiling arrays eliminate the bias of hand-picking
select viral genes to detect and classify entire profiles of
latent gene expression. Tiling arrays also optimize the
detection of viral genes by using multiple unique probes
for one transcript, an advantage over low-density spotting
arrays or individual primer/probe sets used for PCR-based
detection. This approach also efficiently filters viral tran-
scripts from the full cell repertoire by selective sequence
hybridization and normalization. Additionally, the use of
tiling arrays highlights the importance of strand-specificity
in the detection of viral transcripts, as many sense/anti-
sense gene pairs were identified. This observation is con-
sistent with recent strand-specific analysis of Mycoplasma
and mouse genomes [37].
Detection of Viral Genes Without Protein/Transcript
Alignment
Cases in which individual proteins and transcripts are not
correlated remain informative. Instances where proteins
are observed without detectable transcripts may result
from increased protein stability relative to transcript turn-
over. This possibility may explain efficient detection of
MVPs, including capsid, tegument, envelope, and other
associated proteins. Specific genes that appear to be sensi-
tive markers for low levels of lytic induction include MCP
homologues ORF25 of KSHV and BcLF1 of EBV, and PF
homologues ORF59 of KSHV and BMRF1 of EBV. Addi-
tionally, proteins that are stable and expressed from a
small percentage of cells entering the lytic cycle may have
very low levels of transcripts due to the dilution of these
cells by the predominant latent population. This possibility
likely explains most of the KSHV viral proteins detected in
latent BC-1 without associated transcripts.
Instances where transcripts are observed without detect-
able proteins may result from the nature of LC-MS/MS
analysis. We used extensive strong cation exchange (SCX)
fractionation prior to LC-MS/MS analyses to improve the
detection of low abundance KSHV and EBV peptide
sequences over a dynamic range limit based upon previous
experience [38]. However, multiple intrinsic properties of
the digested peptides themselves can also affect the overall
levels of detection and identification, such as their size,
solubility, and electrospray ionization efficiency. Thus,
viral proteins may be under-represented. Finally, peptides
can be detected by MS/MS spectra but not assigned (or
identified) due to the use of filters needed to constrain the
false discovery rate (FDR); in this regard more than half
the peptides detected remain unassigned, typical for MS/
MS studies where FDR is constrained. We note that the
Dresang et al. BMC Genomics 2011, 12:625
http://www.biomedcentral.com/1471-2164/12/625
Page 8 of 15use of the mass spectrometry-generating function (MS-
GF, see Methods) in this work significantly enhanced the
effectiveness of peptide identification at the selected low
FDR. The use of spectral count quantitation has been
shown effective for relative quantitation from LC-MS/MS
[39-41]. Additional explanations for detecting transcripts
without detecting proteins is that not all viral transcripts
encode proteins (e.g., EBERs and PAN), specific transcripts
may be expressed abundantly relative to their encoded
protein, (e.g., BHLF1 and LF3 [42]), and translation from
select transcripts may be inhibited by miRNAs without
significant mRNA destabilization (reviewed in [43]).
Transcriptome and Proteome Analysis Reveal Annotation
Gaps
The combined transcriptome and proteome alignment
validated the detection of known viral genes and identified
novel viral genes. We identified 11 unannotated viral tran-
scripts and 7 unannotated viral proteins (Table 4). The
unannotated transcript antisense-vIL6/ORF2 matched a
recurring novel protein detected in both BC-1 and BCBL-
1 cell lines in both latent and lytic conditions. Chandriani
et al, 2010 [28], identified this transcript associated with
polysomes by immunoprecipitation, consistent with our
detection of this novel protein.
Reporting transcript levels linearly along viral genomes
highlighted specific regions at the 3’-ends of known genes
inconsistent with current annotation. Although most tran-
scripts were within 100 bp of their annotated boundaries,
specific viral genes were significantly extended, including
ORF69 (269 bp extension; Figure 1E) and ORF6 (431 bp
extension; Figure 1A). Thus, linear evaluation of tiling
array data is more informative than using heat map analy-
sis alone. The boundaries of some specific genes can also
be extended based on LC-MS/MS analysis, including K12
and K1. The K12 locus has previously been shown to give
rise to kaposin isoforms B and C, which extend beyond
the 5’-end of kaposin A [16,17]. The K1 gene is known to
vary in KSHV among strains [44-46], although extension
of its protein sequence has not been previously reported.
Many putative peptides were also detected in both
KSHV and EBV (additional file 1, Table S5, Table S6,
and Table S7), consisting of short ORFs with a limited
number of unique sequences and observations. Putative
peptides may arise from novel viral genes, but may also
arise from novel cellular genes or incorrect spectral
assignment of peptides containing multiple coding muta-
tions. Coding mutations will also reduce the detection of
viral peptides as a result of sequence variability among
strains [47,48]. Recent analysis of the antisense-ORF50
region of KSHV supports the hypothesis that this tran-
script gives rise to multiple short peptides that are not
related to the function of their sense counterparts [18].
These short peptides have been proposed to diversify
antigen presentation products in vivo [18]. The functions
of novel viral proteins and transcripts are largely
unknown, and warrant further investigation as to their
roles in the viral life cycle and cancer progression.
Evaluation of Viral Latency and Lytic Reactivation
Induction of the lytic cycle in PEL cell lines was
observed with robust increases in lytic gene expression
at both transcript (Table 1) and protein levels (Table 2).
Lytic manipulation of these cell lines facilitates efficient
detection of multiple viral genes not detected during
latency, and also validates the detection of specific novel
viral genes. Specifically, antisense-vIL6/ORF2 (K1.5; Fig-
ure 1A) of KSHV and antisense-BPLF1 (BURF1; Figure
2C) of EBV were both responsive to lytic induction.
Variations in the patterns of viral gene expression reflect
previous reports of restricted latency, spontaneous lytic
induction, and lytic reactivation of the cell lines assayed
[31,33,34,49-51]. Thus, manipulation of the viral life
cycle has validated this approach to efficiently detect
viral gene products in naturally-infected human cells.
Conclusions
Results Summary
The correlation of detected viral proteins and transcripts
was highly complementary for KSHV’s genes, and to a les-
ser extent for EBV’s genes. Individual genes not detected
by both methods remained informative, providing clues
regarding protein stability, post-transcriptional regulation,
and coding potential. The alignment of viral transcrip-
tomes and proteomes revealed gaps in viral annotation,
including the detection and validation of novel viral genes.
Manipulation of the viral life cycle resulted in the detec-
tion of greater numbers of viral transcripts and proteins in
lytically-induced samples relative to untreated (latent)
samples. Elevated levels of spontaneous lytic induction
versus tight-latency were confirmed for specific PEL and
BL cell lines. This systems biology approach provides a
comprehensive view of viral gene expression that could
not have been attained using either method alone.
Implications
We were able to sensitively detect viral proteins amongst
the full background of cellular proteins in two PEL cell
lines, and we identified candidate viral proteins by using
high-resolution separations and mass spectrometry.
Combining candidate viral proteins with candidate viral
transcripts correlates more directly with the actual abun-
dance and function of these viral products, and provides
insights into their biological importance in disease states.
Additional evaluation of tumor samples or diseased tis-
sues with LC-MS/MS may also help identify cellular pro-
teins biologically important for the development and
progression of human disease. Aligning viral transcripts
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Page 9 of 15detected by custom tiling array to viral proteins detected
by LC-MS/MS analysis proved to be a high-throughput
and sensitive approach to identify known viral genes, to
validate unannotated viral genes, and discover novel viral
genes. The discovery of novel viral transcripts in human
tumors coupled with LC-MS/MS analysis is a potentially




BC-1 [52], JSC-1 [33], BCBL-1 [53], MutuIII [30], and
BJAB [54] cell lines were grown in Roswell Park Memorial
Institute formulation 1640 media with 10% fetal bovine
serum. Growth medium is supplemented with 200 U/mL
penicillin and 200 μg/mL streptomycin, except for samples
prepared for peptide analysis. All cell lines were grown at
37°C with a 5% CO2 humidified atmosphere. BCBL-1 and
BC-1 cells were treated with 20 ng/mL TPA and 0.25 mM
NaB for 48 h to chemically-induce the lytic cycle. Induced
and uninduced cells (no treatment) were counted with
eosin staining to determine the number of live cells for
harvest. Cells were washed once with 1 × phosphate buf-
fered saline and either harvested for RNA, or pelleted and
stored at -80°C prior to peptide analysis.
Total RNA Isolation
Total RNA was isolated using Trizol reagent (Invitrogen,
Carlsbad, CA) as described by Chomczynski and Sacchi,
2006 [55]. RNA was precipitated using the nucleating
agent linear acrylamide (Ambion, Austin, TX) as described
by Gaillard and Strauss, 1990 [56]. RNA samples were
treated with Turbo DNase (Ambion, Austin, TX) to
remove contaminating genomic DNA as per manufac-
turer’si n s t r u c t i o n s .
Design of Custom Tiling Microarrays
Tiling arrays were designed on Agilent Technologies’ cus-
tom microarray 4 × 44K platform (Palo Alto, CA).
Sequences for KSHV, EBV, and a set of control genes (addi-
tional file 1, Table S9) were uploaded in FASTA format in
forward and reverse complement orientations onto the
eArray probe design website (https://earray.chem.agilent.
com/earray/) [57]. KSHV and EBV sequences were
trimmed to one copy unit of major repeats. Initial tiling
d e s i g nc o n s i s t e do f6 0b pp r o b e sw i t h3 0b po fo v e r l a p ,
effectively covering each viral strand twice. Probes were
selected for optimization based on the results of a proof-of-
principle experiment with a KSHV-positive, lytically-
induced sample (data not shown). Probes that generated
spurious signal were removed and gaps were reprobed
employing eArray’s Best-Tm and Best-Distribution meth-
odologies [57]. Gaps were tolerated up to 300 bp or greater
if they spanned repetitive regions; ~6 gaps > 300 bp in
KSHV and ~24 gaps > 300 bp in EBV persisted.
Optimized probes were present on the arrays in tripli-
cate; one set of standardized probes (Agilent Technologies,
Palo Alto, CA) used for quality control and background
subtraction was also present on the arrays. Probes for
KSHV were > 95% identical between type P (subtype C,
NC_009333) and type M (subtype A, U75698.1), or ~97%
with one mismatch. Probes for EBV were > 70% identical
between types 1 (NC_007605) and 2 (NC_009334), or 84%
with one mismatch. This tiling array is available in the
eArray (Agilent Technologies, Palo Alto, CA) microarray
design browser under array name “KSHV_and_EBV” and
design number 027774 [57].
Array Workflow and Statistical Analysis
RNA samples were submitted for labeling, hybridization,
and scanning at the core facility of the McArdle Labora-
tory for Cancer Research (Laboratory of Dr. Chris Brad-
field, Madison, WI). Briefly, first strand cDNA was
synthesized using MMLV-RT and a poly-A-primer with
T7 promoter overhang. Following second-strand cDNA
synthesis, fluorescent dyes (Cy3 or Cy5) were incorporated
through in vitro transcription and cRNA generation. Cy3-
and Cy5-labeled samples were co-hybridized for each
array and scanned. JSC-1, BCBL-1, MutuIII, and BJAB
samples were processed and labeled with Cy3 individually,
while BC-1 latent and BC-1 lytic samples were prepared in
duplicate (technical replicates). BJAB samples labeled with
Cy5 were hybridized as technical replicates for all arrays
slides, but were processed independently (biological repli-
cates) for separate slide hybridizations.
Global and local background fluorescence was adjusted
based on Agilent controls and the Feature Extraction soft-
ware (Agilent Technologies, Palo Alto, CA). Non-specific
hybridization was removed by normalizing to the Cy5
reference channel (BJAB). Cy3 (gProcessedSignal) and Cy5
(rProcessedSignal) values were used to calculate log ratios;
these values were used for all graphic alignments. Microar-
ray data from all eight experiments, including statistical
analyses is briefly described in the “read me” document
additional file 4. Microarray data from all eight experi-
ments is separated by probe type in additional files 5, 6,
and 7 (control, EBV, and KSHV probes, respectively). Raw
microarray data is available on the NCBI-Gene Expression
Omnibus (GEO) website (http://www.ncbi.nlm.nih.gov/
geo/) [58] and on the Pacific Northwest National Labora-
tory (PNNL) website (http://omics.pnl.gov/view/publica-
tion_1036.html) [59] under publication 1036.
Cy3/Cy5 log ratios for each probe were then compared
per array relative to the BJAB/BJAB array control experi-
ment to verify viral transcript detection specific to natu-
rally-infected cell lines. Two-color Limma statistical
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3 web user inter-
face [60]. ~80% of all probes were differentially-expressed
in at least one array group from either MutuIII, BCBL-1,
JSC-1, BC-1 latent (paired group), or BC-1 lytic (paired
group) arrays using a <0.05 P-value cutoff (additional
files 8, 9 and 10). Expression profiles were also compared
pairwise across samples according to viral transcriptome
using Pearson’s correlation coefficients (additional file 1,
Table S4).
We then assessed triplicate probe variance within each
array using Limma statistical analysis with R-Bioconduc-
tor [61-63]. Because most of the probes are predicted to
have different signals between the two channels, tradi-
tional normalization methods, which usually assume a
bulk of non-differentially expressed genes in the data
set, cannot be readily used. Instead, we normalized all
signals against the mean expression levels of three
house-keeping genes (GAPDH, ACTA1, and TUBA1B)
in each channel. The P-values for differential expression
between the two channels are computed with Limma
using the three triplicate probes per feature, and then
adjusted for multiple testing according to Benjamini and
Hochberg’s false discovery rate method [64]. No P-
values < 0.01 were associated with any viral probe set
from the BJAB/BJAB control experiment (additional file
11).
Transcript Quantitation
MMLV-RT has stalling and residual RNaseH activities
[65], and second strand synthesis is random, generating
double-stranded products from multiple points along the
full-length transcript. These effects generate a 3’-bias in
the labeled transcripts. Because the 3’-ends of viral genes
are associated with the least variance among triplicate
probes based on mapped P-values (data not shown), the
relative levels of individual transcripts across multiple
samples were assessed based on the data from 10 probe
sets (in triplicate) at their 3’-end. Additional adjustments
were made for overlapping transcripts. Transcript levels
for all genes were determined for each array experiment.
The standard deviation (SD) was calculated from the
averages of all EBV and KSHV transcripts corresponding
to the BJAB/BJAB control experiment, where SD ≈ 1.13.
Individual transcripts were considered positively-detected
if both the average and the average - 1SD for each probe
set was ≥1.25-fold (~2SD) over the reference sample. This
cutoff eliminates all false positives in samples negative for
KSHV, EBV, or both viruses, while minimizing false nega-
tives. The alignment of proteins with transcripts using cut-
offs of 1-, 1.5-, and 2-fold normalized signal was also
evaluated (additional file 1, Table S8). Higher cutoffs
result in decreased alignment of detected proteins-to-tran-
scripts, while the lower cutoff results in increased align-
ment of detected proteins-to-transcripts. The alignments
of detected transcripts-to-proteins with adjusted cutoffs
variably increase or decrease; this reflects more sensitive
protein detection than transcript detection, but also more
comprehensive transcript detection than protein detection.
Cy3 fluorescent bleed-over is observed in the Cy5 chan-
nel, rendering normalization overly-conservative; probes
flagged as saturated in the Cy3 channel are over-exagger-
ated in the Cy5 channel as a consequence of fluorescent
bleed-over. If a given transcript was saturated at the 3’-end
in more than half of the samples, then its levels were cal-
culated from unsaturated probes tiled more towards its 5’-
end. If a particular transcript was only saturated in a few
of the samples, e.g., lytic BC-1 samples alone, then tran-
script levels were calculated as usual for unsaturated sam-
ples while the saturated samples were reported as
“>50*Sat” over reference, roughly corresponding to the
greatest normalized signal observed within the unsaturated
range (>50-fold). The loss of normalized signal due to high
fluorescent bleed-over has not been corrected in the nor-
malized maps.
Sample Preparation for LC-MS/MS
BCBL-1 and BC-1 cell pellets shipped frozen on dry ice to
PNNL were resuspended, disrupted by vigorous vortexing,
lysed, and finally denatured and reduced in a solution of 8
M urea and 5 mM dithiothreitol at 37°C for 60 min in a
thermomixer at 800 rpm. A protein assay (bicinchoninic
acid) BCA (Pierce, Rockford, IL) was performed on the
resultant lysate, noting volume and protein concentration.
Samples were then diluted 8-fold with 50 mM NH4HCO3
pH 8.0 buffer. CaCl2 (1 mM final concentration) and
sequencing-grade modified porcine trypsin (Promega,
Madison, WI) were added to all protein samples at a 1:50
(w/w) trypsin-to-protein ratio. Samples were digested for 3
h at 37°C. Peptides were then isolated using Discovery C18
50 mg/mL solid phase extraction tubes (Supelco, St. Louis,
MO). A BCA assay (Pierce, Rockford, IL) was performed
to determine relative peptide concentration. The samples
were stored at -80°C until separation.
Peptide samples were subjected to SCX chromatography
using a Polysulfoethyl A 200 × 2.1-mm, 5 μm, 300 Å col-
umn (PolyLC, Columbia, MD) preceded by a 10 × 2.1-mm
guard column with a flow rate of 0.2 mL/min. For each
sample 300 μg of digested and cleaned peptides were
diluted in 900 μL of solvent A (10 mM ammonium for-
mate, 25% acetonitrile, pH 3.0) and loaded onto the col-
umn. The separations were performed with an Agilent
1100 HPLC system utilizing a DAD UV/Vis detector,
autosampler, fraction collector and quaternary pump (Agi-
lent Technologies, Palo Alto, CA). Mobile phases consist
of solvent A, and solvent B (500 mM ammonium formate,
25% acetonitrile, pH 6.8). Once the sample was injected,
the gradient was isocratic for 10 min at 100% solvent A,
followed by an initial gradient from 100% solvent A to
Dresang et al. BMC Genomics 2011, 12:625
http://www.biomedcentral.com/1471-2164/12/625
Page 11 of 1550% solvent B for 40 min. A steeper gradient to 100% sol-
vent B lasting 10 min was then performed and held isocra-
tically at 100% solvent B for 10 min. A total of 27 fractions
were collected over the initial 70 min of the gradient. The
fractions were lyophilized to dryness and stored at -80°C
until analysis.
Reversed-Phase LC Separation and MS/MS Analysis
Separated fractions were dissolved in 30 μLo f2 5m M
NH4HCO3 and 10 μL of each fraction was analyzed using
LC-MS/MS. The analytical platform couples a constant
pressure (5000 psi) capillary LC system 75 μm i.d. × 360
μm o.d. × 65 cm capillary (Polymicro reversed phase
Technologies Inc., Phoenix, AZ) with an LTQ ion trap
mass spectrometer (ThermoFinnigan, San Jose, CA) and
an electrospray ionization source manufactured in-house
at PNNL. The instrument was operated in data-dependent
mode with an m/z range of 400-2000. The 10 most abun-
dant ions from MS analysis were selected for further MS/
MS analysis, using a normalized collision energy setting of
35%. A dynamic exclusion of 1 min was applied to reduce
repetitive analysis of the same abundant precursor ion.
Proteomic Data Analysis
ExtractMSn (version 4.0) and SEQUEST (Version v.27,
Rev 12, Thermo Fisher Scientific, Waltham MA) analysis
software was used to match the MS/MS fragmentation
spectra to peptide sequences [66]. The search was per-
formed using default parameters with no-enzyme rules
within a ± 1.5 Da parent mass window, ± 0.5 Da fragment
mass window, average parent mass, and monoisotopic
fragment mass. Separate databases were generated for
peptide spectral assignment for the BC-1 and BCBL-1
samples. The databases searched against included known
proteins from EBV, KSHV, and a comprehensive Human
SwissProt protein collection (uniprot_sprot_human.dat.gz
downloaded 4/20/2010, 20277 protein entries) [67]. These
databases also included putative proteins in any of the 6
frames from EBV and KSHV that were at least 10 amino
acids in length between adjacent termination codons. The
EBV strain in BC-1 has been characterized to have varying
homology to both type 1 (NC_007605) and type 2
(NC_009334) strains [68]; both sequences were used to
assign peptide spectra in BC-1 samples. KSHV type M
(U75698.1), an A subtype of KSHV, was initially generated
from a BC-1 and BC-2 library [13]; this KSHV sequence
was used for assigning peptide spectra in BC-1 samples. A
pre-publication draft of a KSHV library from BCBL-1
(HQ404500.1) was previously sequenced by the labs of Dr.
Thomas Schulz and Dr. Cornelia Henke-Gendo [69]; the
K1 gene from this library shares 100% identity to a pre-
viously sequenced K1 gene from BCBL-1 [44]. EBV
sequences were not used to assign peptide spectra in the
BCBL-1 samples, as these cells are EBV-negative.
MS-GF values were generated for each peptide-spectral
match [70]. MS-GF values are a peptide spectral prob-
ability that provides a statistically significant computation
for each spectral identification [70], and are used to vali-
date peptide identifications. Peptide identifications were
retained only for peptides with a minimum peptide MS-
GF value < 1 × 10
-9, corresponding to an estimated 1%
FDR [66,70,71]. After peptides were assigned to specific
genomes, either human, KSHV, or EBV, these amino acid
sequences were then cross-checked by using the Basic
Local Alignment Search Tool, either peptide alignments
to corresponding proteins and/or translated alignments
against each of these genomes. Those amino acid
sequences that matched exactly to known human pep-
tides or matched exactly to putative translated nucleo-
tides in the human genome were omitted from EBV and
KSHV genome assignments. LC-MS/MS data is accessi-
ble through the PNNL website (http://omics.pnl.gov/
view/publication_1036.html) [59] under publication 1036.
Additional material
Additional file 1: Table S1, Normalized Levels of KSHV’s Transcripts;
Table S2, Normalized Levels of EBV’s Transcripts; Table S3, Raw
Fluorescent Levels of Cellular and Reporter Transcripts; Table S4,
Pearson’s Correlation Coefficients of Viral Transcriptomes; Table S5, KSHV
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Additional file 3: Figure S2, EBV Aligned Gene Annotation,
Transcripts, & Proteins. This powerpoint file contains the alignments for
all cell lines and conditions assayed, corresponding to EBV’s genome.
Additional file 4: Micoarray Data from 8 Experiments (Read Me).
This word document contains the descriptions for all microarray data
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